News by Subject
News by Disease
News by Date
Post Your News
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
US & Canada
Post an Event
News | News By Subject | News by Disease |
News By Date | Search News
NBE-Therapeutics Announces Successful Validation Of Its SMAC-Technology For The Generation Of Antibody Drug Conjugates (ADCs)
2/21/2014 8:53:03 AM
Basel, Switzerland, February 21, 2014 / B3C newswire / - NBE-Therapeutics (“NBE”) today announced that it has presented the successful validation of its enzymatic SMAC™-Technology for the generation of potent next-generation antibody drug conjugates (ADCs) at the international World ADC summit 2014 in Frankfurt, Germany, this week.
NBE’s patent-pending SMAC™-Technology (SMAC = sortase-mediated antibody conjugation) utilizes highly selective sortase enzymes for site-specific and efficient conjugation of toxic payloads to therapeutic antibodies. SMAC™-Technology allows the generation of homogeneous ADC drug substances, representing an improvement to current clinical-stage ADCs that are heterogeneous also comprising molecules with undesired properties.
In proof-of-concept studies it was demonstrated that SMAC™ generated ADCs display the same potencies in cancer cell killing experiments as commercially available benchmark ADCs composed of identical antibody and toxin, even when significantly smaller amount of toxic payload was conjugated.
NBE-Therapeutics’ novel ADC technology has the potential to improve the therapy of cancer. The company is now planning to leverage its validated SMAC™-Technology for the development of a preclinical and clinical pipeline of next-generation ADC products, aimed at providing improved targeted therapies for difficult to treat cancers of e.g. breast, ovary, lung, colon and pancreas.
About NBE-Therapeutics AG
NBE-Therapeutics AG is a biotechnology company located in Basel, Switzerland, focusing on the development of antibody drug conjugates (ADCs) for the therapy of cancer. ADCs are a new type of targeted therapy, in which highly potent cellular toxins (toxic payloads) are conjugated to cancer-specific antibodies allowing the targeted destruction of cancer cells without affecting healthy cells or tissue. The company has developed Transpo-mAb™, a fully human therapeutic antibody discovery platform, as well as the SMAC™-Technology, an enzymatic payload conjugation platform, for the generation of homogeneous next-generation ADCs.
Ulf Grawunder, CEO
Technology Park Basel
Hochberger Strasse 60C
Help employers find you! Check out all the jobs and post your resume.